Analyst Rating Update on Seattle Genetics (SGEN)

Seattle Genetics (NASDAQ:SGEN) : Zacks Investment Research ranks Seattle Genetics (NASDAQ:SGEN) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 11 research analysts is 2, which indicates as a Buy.

Seattle Genetics (NASDAQ:SGEN) : The highest level Seattle Genetics (NASDAQ:SGEN) is projected to reach is $65 for the short term and the lowest estimate is at $33. The consolidated price target from 10 rating analysts who initiate coverage on the stock is $45.2 and the possibility the share price can swing is $9.73.

For the current week, the company shares have a recommendation consensus of Buy.

Seattle Genetics (NASDAQ:SGEN): stock turned positive on Tuesday. Though the stock opened at $37.08, the bulls momentum made the stock top out at $38.82 level for the day. The stock recorded a low of $37.05 and closed the trading day at $38.77, in the green by 6.60%. The total traded volume for the day was 850,600. The stock had closed at $36.37 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Siegall Clay B, director officer (President and CEO) of Seattle Genetics Inc /Wa, had unloaded 22,083 shares at an average price of $43.57 in a transaction dated on June 6, 2016. The total value of the transaction was worth $962,156.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.